Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

ements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the results of the subsequent stage for this trial will not be consistent with the results of the first stage. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on ... its unaudited financial results for the second quarter ... quarter ended June 30, 2014: , Revenue increased ... RMB638.8 million in the second quarter of 2013 ...
(Date:8/27/2014)... 2014 TWi Pharmaceuticals, Inc. (4180.TT) today announced ... United States Food and Drug Administration (FDA) on ... acetate 125mg/ml oral suspension, the generic equivalent to ... and under Hatch Waxman rules, it will be ... has completed the pre-launch preparation of the generic ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report: Collaborative R&D Terms & ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Collaborative ... and Diagnostics report provides comprehensive understanding and ... and agreements entered into by the worlds ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid ... restoration of joint structure was observed in the studies, which were ... at Southern Research Institute. , , As a therapeutic ...
... REDWOOD CITY, Calif., July 7 Relievant Medsystems, Inc., ... low back pain, reported today that it has completed ... was led by Morgenthaler Ventures with existing investors Canaan ... Partners participating. The company also announced that Morgenthaler ...
Cached Medicine Technology:Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis 2Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis 3Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 3
(Date:8/28/2014)... August 28, 2014 Top 10 ... web hosting companies and announces Bluehost, HostMonster ( ... suppliers for the webmasters worldwide who want to ... , As the world’s most popular server-side scripting ... many other general-purpose programs. It is now installed ...
(Date:8/28/2014)... ChiLiving® will host its inaugural ... at holistic retreat center, Om Sanctuary. This active ... and Danny Dreyer, offers beginner to seasoned runners ... support a lifetime of pain-free, injury-free movement in ... the heart of the Blue Ridge Mountains during ...
(Date:8/28/2014)... 28, 2014 Now in its 4th year, ... started in 2011 by two brain aneurysm survivors. The ongoing ... awareness, provide education to help increase early detection and to ... a brain aneurysm. We hope that you will be able ... at the 4th Annual Step for Hope Run/ Walk on ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is ... Zebras In Tiaras, to benefit the Immune Deficiency Foundation ... 26, 2014 in Foley Square, New York. IDF ... immunodeficiency diseases (PI) are a group of more than ... the body’s immune system is missing or functions improperly. ...
(Date:8/28/2014)... Livermore, CA (PRWEB) August 28, 2014 ... newest California physician, James Patel M.D. of Livermore, California. ... the best and most qualified physicians, and in accordance ... and our patients to Dr. Patel’s practice. , Initially ... at a young age, Dr. Patel was shaped by ...
Breaking Medicine News(10 mins):Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 3Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4
... which comes from the foxglove plant, is normally used to ... the heart and treat heart diseases. The chemical nature of ... University of Wisconsin-Madison to make the drug fight against cancer//., ... works by changing the sugars attached to the drug. By ...
... According to a latest study researchers say health professionals ... manage the risks associated with over the counter drugs. ... one of the most common condition that people choose ... of the other commonly treated ailments include heartburn, migraine, ...
... stutent multi-kinase inhibitors against cancer is undergoing phase 3 ... this years ASCO (American Society of Clinical Oncology) conference. ... mechanism of action – known as Multi-kinase inhibitors. These ... and are found to be very effective. This two ...
... two different types of low fat, low cholesterol diets researchers ... diet consisting of lean meats and other low fat foods ... percent. However, those who consumed a diet rich in plant-based ... as well, lowering their LDL levels by about 9.4 percent. ...
... Researchers say Kelp seaweed may be the next food ... findings from an animal study conducted at the University ... the seaweed effectively reduced levels of estradiol, // a ... rats. The rats also experienced a lengthening of their ...
... say an indirect CT venography ( CTV ) could identify ... break free, travel to the lung, and block an artery ... arteries are not visible in a commonly used lung scan, ... presence of these blood clots in the lung. ...
Cached Medicine News:
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Brightness acuity tester....
Medicine Products: